Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunotec a direct-to-consumer company, a leader in the nutritional industry and Institut de recherches cliniques de Montréal (IRCM) are pleased to announce important findings from this double-blind-randomized controlled study in elderly adults between the ages of 65 and 88.
Subscribe to our email newsletter
The results show that Immunoca® with statistical significance imparts a performance benefit of approximately 10 per cent in muscle strength. This is very relevant for healthy aging, as the process is typically associated with a decrease in muscle strength that may contribute to disability in old age and to loss of quality of life.
The Principal Investigator, Dr. Rémi Rabasa-Lhoret, MD, PhD, endocrinologist, Director of the Metabolic Diseases research unit (IRCM), Associate Research Professor – Nutrition Department of Université de Montréal – Faculty of Medicine, and FRQS senior scholar, J-A De Sève research chair, is encouraged with the findings and the implications of the trial, saying "maintaining and improving muscle strength is important and feasible in elderly subjects.
We observed that the added benefit related to the addition of Immunocal to a resistance training program raises hope for improving the reward of exercise for elderly subjects and will lead to interesting and new research questions".
The manuscript was spearheaded by Dr. Antony Karelis, PhD, Professeur Département de kinanthropologie, Université du Québec à Montréal and co-investigator in this trial. Dr. Karelis expressed his views by saying "the addition of Immunocal to a resistance training program was able to improve leg muscle strength even more when compared to taking another protein (casein) with the same resistance training program.
Health professionals (kinesiologists and nutritionists) may want to consider Immunocal during implementation of their exercise and nutritional intervention programs in the elderly population".
"The completion of this research study in an elderly population adds to our significant accomplishments and continued commitment in research for wellness", said Mr. Charles Orr, CEO of Immunotec Inc.
"These results are congruent with our previous work where we demonstrated a significant performance advantage in a younger population of 20-year-olds consuming Immunocal" said John H. Molson, VP R&D, Immunotec Inc.